Evidence map›Paper›PMID 27099835›Full record

ArticleEuropean thyroid journal2016

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Luigi Bartalena, Lelio Baldeschi, Kostas Boboridis, Anja Eckstein, George J Kahaly, Claudio Marcocci, Petros Perros, Mario Salvi, Wilmar M Wiersinga, European Group on Graves' Orbitopathy (EUGOGO)

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European thyroid journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 452 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
452citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04876534 phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy

TypeinterventionalSponsorFondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoRan2019 to 2023Enrolled64ConditionsGraves OphthalmopathyArmsTocilizumab 20 Mg/mL Intravenous Solution, MethylPREDNISolone Injectable Solution
NCT04976816 phase2 / phase3completednot on this mapstarted 2021, after this paper: background citation

Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis

TypeinterventionalSponsorAssiut UniversityRan2021 to 2023Enrolled92ConditionsThyroid Eye DiseaseArmsperi-levator betamethasone injection, peri-levator triamcinolone injection, peri-levator and retrobulbar betamethasone injection, peri-levator and retrobulbar triamcinolone injection
3 · Its place in the literature

Who cites it

452 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Patterns of Teprotumumab-Induced Hearing Dysfunction: A Systematic Review.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. The EANM guideline on radioiodine therapy of benign thyroid disease.European journal of nuclear medicine and molecular imaging · 2023
    Guideline
  7. Pooled it
  8. Rituximab for thyroid-associated ophthalmopathy.The Cochrane database of systematic reviews · 2022
    Pooled it
  9. Pooled it
  10. Guideline
  11. Trial
  12. Trial
  13. Trial
  14. Improvement of asymmetric thyroid eye disease with teprotumumab.The British journal of ophthalmology · 2022
    Trial
  15. Article
  16. Pupillometric alterations in Graves' disease: Beyond thyroid functional status.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Observational

392 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luigi BartalenaDepartment of Clinical and Experimental Medicine, University of Insubria, Endocrine Unit, Ospedale di Circolo, Varese, Italy.
Lelio BaldeschiDepartment of Ophthalmology, Hospital Saint Luc, Catholic University of Louvain, Brussels, Belgium.
Kostas BoboridisOphthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Anja EcksteinZentrum für Augenheilkunde, Universitätsklinikum Essen, Essen, Germany.
George J KahalyDepartment of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany.
Claudio MarcocciDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Petros PerrosDepartment of Endocrinology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Mario SalviGraves' Orbitopathy Center, Endocrinology, Fondazione Ca' Granda IRCCS, University of Milan, Milan, Italy.
Wilmar M WiersingaDepartment of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
European Group on Graves' Orbitopathy (EUGOGO)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient's quality of life. Local measures (artificial tears, ointments and dark glasses) and control of risk factors for progression (smoking and thyroid dysfunction) are recommended for all patients. In mild GO, a watchful strategy is usually sufficient, but a 6-month course of selenium supplementation is effective in improving mild manifestations and preventing progression to more severe forms. High-dose glucocorticoids (GCs), preferably via the intravenous route, are the first line of treatment for moderate-to-severe and active GO. The optimal cumulative dose appears to be 4.5-5 g of methylprednisolone, but higher doses (up to 8 g) can be used for more severe forms. Shared decision-making is recommended for selecting second-line treatments, including a second course of intravenous GCs, oral GCs combined with orbital radiotherapy or cyclosporine, rituximab or watchful waiting. Rehabilitative treatment (orbital decompression surgery, squint surgery or eyelid surgery) is needed in the majority of patients when GO has been conservatively managed and inactivated by immunosuppressive treatment.

Indexed as

CyclosporineEyelid surgeryGlucocorticoidsGraves’ orbitopathyOrbital decompressionOrbital radiotherapyRituximabSeleniumSquint surgery

Identifiers

PMID27099835
PMCPMC4836120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.